← Back to patent-cliff list
Antineoplaston As2-1/Antineoplaston A10
Tier C — Watch / tradeAntineoplaston As2-1/Antineoplaston A10
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：Glioma, Non-Hodgkin lymphoma, 呼吸道肿瘤, Prostate cancer, Waldenström macroglobulinaemia, Multiple myeloma, Melanoma, Ovarian cancer
Regional status
US
Discontinued
1966-07-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Antineoplaston As2-1/Antineoplaston A10?
Approved indications include: Glioma, Non-Hodgkin lymphoma, 呼吸道肿瘤, Prostate cancer, Waldenström macroglobulinaemia, Multiple myeloma, Melanoma, Ovarian cancer.
When does the Antineoplaston As2-1/Antineoplaston A10 patent expire?
No public expiry year is available for Antineoplaston As2-1/Antineoplaston A10 yet; this page updates once verified.
How do I get a quote for Antineoplaston As2-1/Antineoplaston A10 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-18